Peculiarities of management of pregnant patients having inflammatory bowel diseases in hospital conditions: Literature review

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Multiannual observations of pregnant patients with inflammatory bowel diseases (IBD) allow us to conclude that many of their adverse outcomes are associated with the activity of the disease itself, and not with the use of genetically engineered biological drugs or immunosuppressive therapy. Most drugs used to treat patients with ulcerative colitis (UC) and Crohn’s disease (CD) are considered to be safe during pregnancy. To minimize the risks of hospitalization of IBD patients, gastroenterologists need to advise them planning pregnancy, discussing with them not only the potential risks of exacerbation of UC or CD during gestation, but also the necessity of systematic visits to the doctor, as well as the importance of following prescribed plan of treatment, as well as regular obstetric and gastroenterological monitoring.

About the authors

Oleg V. Knyazev

A.S. Loginov Moscow Clinical Scientific and Practical Center of the Department of Healthcare of Moscow; A.N. Ryzhikh National Medical Research Center of Coloproctology of the Ministry of Healthcare of Russia

Author for correspondence.
Email: oleg7@bk.ru
ORCID iD: 0000-0001-7250-0977
SPIN-code: 3268-0360

MD, Dr. Sci. (Medicine), head of the Department of intestinal pathology; chief external expert-gastroenterologist of the Department of Healthcare of Moscow, professor of the Department of science and education

Russian Federation, Moscow; Moscow

Anna V. Kagramanova

A.S. Loginov Moscow Clinical Scientific and Practical Center of the Department of Healthcare of Moscow; Research Institute of Healthcare and Medical Management Organization of the Department of Healthcare of Moscow

Email: a.kagramanova@mknc.ru
ORCID iD: 0000-0002-3818-6205
SPIN-code: 4086-6745

MD, PhD (Medicine), senior researcher at the Department of intestinal pathology; leading specialist of the organizational and methodological Department for coloproctology

Russian Federation, Moscow; Moscow

Nina A. Fadeeva

A.S. Loginov Moscow Clinical Scientific and Practical Center of the Department of Healthcare of Moscow; Research Institute of Healthcare and Medical Management Organization of the Department of Healthcare of Moscow; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Email: n.fadeeva@mknc.ru
ORCID iD: 0000-0002-0524-2514
SPIN-code: 6047-7590

MD, PhD (Medicine), head of the Department of gastroenterology; leading specialist of the organizational and methodological Department of gastroenterology; 

Russian Federation, Moscow; Moscow; Moscow

Tatyana V. Shkurko

A.N. Ryzhikh National Medical Research Center of Coloproctology of the Ministry of Healthcare of Russia; Research Institute of Healthcare and Medical Management Organization of the Department of Healthcare of Moscow

Email: shkurkotania@yandex.ru
ORCID iD: 0000-0002-7502-2437
SPIN-code: 9073-3362

MD, PhD (Medicine), deputy general director of the Association of Coloproctologists of Russia, head of the Department of science and education; head of the organizational and methodological Department for coloproctology

Russian Federation, Moscow; Moscow

References

  1. Feuerstein J.D., Cheifetz A.S. Management of inpatient inflammatory bowel disease. Springer, New York, NY. 2021; 292 pp. https://doi.org/10.1007/978-1-0716-1987-2_13. ISBN: 978-1-0716-1986-5.
  2. Miller J.P. Inflammatory bowel disease in pregnancy: A review. J R Soc Med. 1986; 79(4): 221–25. https://doi.org/10.1177/014107688607900410. PMID: 2871190. PMCID: PMC1290279.
  3. de Lima-Karagiannis A., Zelinkova-Detkova Z., van der Woude C.J. The effects of active IBD during pregnancy in the era of novel IBD therapies. Am J Gastroenterol. 2016; 111(9): 1305–12. https://doi.org/10.1038/ajg.2016.254. PMID: 27349339.
  4. Watanabe C., Nagahori M., Fujii T. et al. Non-adherence to medications in pregnant ulcerative colitis patients contributes to disease flares and adverse pregnancy outcomes. Dig Dis Sci. 2021; 66(2): 577–86. https://doi.org/10.1007/s10620-020-06221-6. PMID: 32249373.
  5. Puri A., Bharadwaj V., Sachdeva S. Extent of disease is a major outcome predictor in patients with ulcerative colitis and pregnancy. Indian J Gastroenterol. 2015; 34(2): 108–11. https://doi.org/10.1007/s12664-015-0542-y. PMID: 25895048.
  6. Getahun D., Fassett M.J., Longstreth G. et al. Association between maternal inflammatory bowel disease and adverse perinatal outcomes. J Perinatol. 2014; 34(6): 435–40. https://doi.org/10.1038/jp.2014.41. PMID: 24651735.
  7. Bortoli A., Pedersen N., Duricova D. et al. Pregnancy outcome in inflammatory bowel disease: Prospective European case-control ECCO – EpiCom study, 2003–2006. Aliment Pharmacol Ther. 2011; 34(7): 724–34. https://doi.org/10.1111/j.1365-2036.2011.04794.x. PMID: 21815900.
  8. Riis L., Vind I., Politi P. et al. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol. 2006; 101: 1539–45. https://doi.org/10.1111/j.1572-0241.2006.00602.x. PMID: 16863558.
  9. Dubinsky M.., Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis. 2008; 14: 1736–50. https://doi.org/10.1002/ibd.20532. PMID: 18626967.
  10. Abramson D., Jankelson I.R., Milner L.R. Pregnancy in idiopathic ulcerative colitis. Am J Obstet Gynecol. 1951; 61: 121–29. https://doi.org/10.1016/0002-9378(51)90014-2. PMID: 14799518.
  11. Willoughby C.P., Truelove S.C. Ulcerative colitis and pregnancy. Gut. 1980; 21(6): 469–74. https://doi.org/10.1136/gut.21.6.469. PMID: 6107262. PMCID: PMC1419661.
  12. Greenfield C., Pounder R.E., Craft I.L. et al. Severe ulcerative colitis during successful pregnancy. Postgrad Med J. 1983; 59: 459–61. https://doi.org/10.1136/pgmj.59.693.459. PMID: 6622331. PMCID: PMC2417568.
  13. Bohe M.G., Ekelund G.R., Genell S.N. et al. Surgery for fulminating colitis during pregnancy. Dis Colon Rectum. 1983; 26(2): 119–22. https://doi.org/10.1007/BF02562590. PMID: 6822171.
  14. Anderson J.B., Turner G.M., Williamson R.C. Fulminant ulcerative colitis in late pregnancy and the puerperium. J R Soc Med. 1987; 80(8): 492–94. https://doi.org/10.1177/014107688708000812. PMID: 3656334. PMCID: PMC1290955.
  15. Beniada A., Benoist G., Maurel J., Dreyfus M. Inflammatory bowel disease and pregnancy: Report of 76 cases and review of the literature. J Gynecol Obstet Biol Reprod. 2005; 34(6): 581–88. https://doi.org/10.1016/s0368-2315(05)82883-2. PMID: 16208201.
  16. Haq A.I., Sahai A., Hallwoth S. et al. Synchronous colectomy and cesarean section for fulminant ulcerative colitis: Case report and review of the literature. Int J Color Dis. 2006; 21(5): 465–69. https://doi.org/10.1007/s00384-005-0027-z. PMID: 16133002.
  17. Orabona R., Valcamonico A., Salemme M. et al. Fulminant ulcerative colitis in a healthy pregnant woman. World J Gastroenterol. 2015; 21(19): 6060–64. https://doi.org/10.3748/wjg.v21.i19.6060. PMID: 26019473. PMCID: PMC4438043.
  18. Uchino M., Ikeuchi H., Matsuoka H. et al. Surgery for severe ulcerative colitis during pregnancy: Report of two cases. Case Rep Gastroenterol. 2015; 9(1): 74–80. https://doi.org/10.1159/000381141. PMID: 25960728. PMCID: PMC4410590.
  19. Brunelli R., Perrone S., Perrone G. et al. New-onset ulcerative colitis in pregnancy associated to toxic megacolon and sudden fetal decompensation: Case report and literature review. J Obstet Gynaecol Res. 2019; 45(7): 1215–21. https://doi.org/10.1111/jog.13996. PMID: 31064034.
  20. Cappell M.S., Colon V.J., Sidhom O.A. A study at 10 medical centers of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups. Dig Dis Sci. 1996; 41(12): 2353–61. https://doi.org/10.1007/BF02100127. PMID: 9011442.
  21. Hartgill T.W., Bergersen T.K., Pirhonen J. Core body temperature and the thermoneutral zone: A longitudinal study of normal human pregnancy. Acta Physiol (Oxf). 2011; 201(4): 467–74. https://doi.org/10.1111/j.1748-1716.2010.02228.x. PMID: 21087419.
  22. Pillay V., Savage N., Laburn H. Interleukin-1 receptor antagonist in newborn babies and pregnant women. Pflugers Arch. 1993; 424(5–6): 549–55. https://doi.org/10.1007/BF00374921. PMID: 8255740.
  23. Killeen S., Gunn J., Hartley J. Surgical management of complicated and medically refractory inflammatory bowel disease during pregnancy. Color Dis. 2017; 19(2): 123–38. https://doi.org/10.1111/codi.13413. PMID: 27317641.
  24. Winter R., Norgard B.M., Friedman S. Treatment of the pregnant patient with inflammatory bowel disease. Inflamm Bowel Dis. 2016; 22(3): 733–44. https://doi.org/10.1097/MIB.0000000000000625. PMID: 26658216.
  25. Friedman S. Gestational weight gain: A new factor influencing pregnancy outcomes in women with inflammatory bowel disease. Dig Dis Sci. 2017; 62(8): 2070–71. https://doi.org/10.1007/s10620-017-4635-6. PMID: 28577246.
  26. Beaulieu D.B., Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol Clin N Am. 2011; 40(2): 399–413, ix. https://doi.org/10.1016/j.gtc.2011.03.006. PMID: 21601787.
  27. Cornish J., Tan E., Teare J. et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007; 56(6): 830–37. https://doi.org/10.1136/gut.2006.108324. PMID: 17185356. PMCID: PMC1954859.
  28. Leung Y.P., Kaplan G.G., Coward S. et al. Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease. J Crohns Colitis. 2015; 9(3): 223–30. https://doi.org/10.1093/ecco-jcc/jjv006. PMID: 25576754.
  29. Lin K., Martin C.F., Dassopoulos T. et al. 2 pregnancy outcomes amongst mothers with inflammatory bowel disease exposed to systemic cortico-steroids: Results of the PIANO registry. Gastroenterology. 2014; 146(5): S-1. https://doi.org/10.1016/S0016-5085(14)60002-0.
  30. Truta B. Potential risks of immunosuppressant drugs to the pregnant patient: ACG/Radhika Srinivasan Gender-Based Research Award: 2322. Am J Gastroenterol. 2015; 110: S966.
  31. Mitchell K., Kaul M., Clowse M. The management of rheumatic diseases in pregnancy. Scand J Rheumatol. 2010; 39(2): 99–108. https://doi.org/10.3109/03009740903449313. PMID: 20337545. PMCID: PMC3724464.
  32. Broms G., Granath F., Linder M. et al. Complications from inflammatory bowel disease during pregnancy and delivery. Clin Gastroenterol Hepatol. 2012; 10(11): 1246–52. https://doi.org/10.1016/j.cgh.2012.08.018. PMID: 22922307.
  33. Bates S.M., Rajasekhar A., Middeldorp S. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Venous thromboembolism in the context of pregnancy. Blood Adv. 2018; 2(22): 3317–59. https://doi.org/10.1182/bloodadvances.2018024802. PMID: 30482767. PMCID: PMC6258928.
  34. van der Woude C.J., Ardizzone S., Bengtson M.B. et al. European Crohn’s and Colitis Organization. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015; 9(2): 107–24. https://doi.org/10.1093/ecco-jcc/jju006. PMID: 25602023.
  35. Tsigkas G., Davlouros P., Despotopoulos S. et al. Inflammatory bowel disease: A potential risk factor for coronary artery disease. Angiology. 2017; 68(10): 845–49. https://doi.org/10.1177/0003319717690993. PMID: 28122463.
  36. Tandon P., Leung K., Yusuf A., Huang V.W. Noninvasive methods for assessing inflammatory bowel disease activity in pregnancy: A systematic review. J Clin Gastroenterol. 2019; 53(8): 574–81. https://doi.org/10.1097/MCG.0000000000001244. PMID: 31306343.
  37. Julsgaard M., Hvas C.L., Gearry R.B. et al. Fecal calprotectin is not affected by pregnancy: Clinical implications for the management of pregnant patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017; 23(7): 1240–46. https://doi.org/10.1097/MIB.0000000000001136. PMID: 28498159.
  38. Balint A., Berenyi A., Farkas K. et al. Pregnancy does not affect fecal calprotectin concentration in healthy women. Turk J Gastroenterol. 2017; 28(3): 171–75. https://doi.org/10.5152/tjg.2017.16711. PMID: 28336498.
  39. Kammerlander H., Nielsen J., Kjeldsen J. et al. Fecal calprotectin during pregnancy in women with moderate-severe inflammatory bowel disease. Inflamm Bowel Dis. 2018; 24(4): 839–48. https://doi.org/10.1093/ibd/izx055. PMID: 29506137.
  40. Ludvigsson J.F., Lebwohl B., Ekbom A. et al. Outcomes of pregnancies for women undergoing endoscopy while they were pregnant: A nationwide cohort study. Gastroenterology. 2017; 152(3): 554–63.e9. https://doi.org/10.1053/j.gastro.2016.10.016. PMID: 27773807.
  41. Ray J.G., Vermeulen M.J., Aditya Bharatha A. et al. Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA. 2016; 316(9): 952–61. https://doi.org/10.1001/jama.2016.12126. PMID: 27599330.
  42. Reddy D., Murphy S.J., Kane S.V. et al. Relapses of inflammatory bowel disease during pregnancy: In-hospital management and birth outcomes. Am J Gastroenterol. 2008; 103(5): 1203–9. https://doi.org/10.1111/j.1572-0241.2007.01756.x. PMID: 18422816.
  43. Ghalandari N., Dolhain R.J.E.M., Hazes J.M.W. et al. The pre- and post- authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation. Br J Clin Pharmacol. 2020; 86(3): 580–90. https://doi.org/10.1111/bcp.14145. PMID: 31633830. PMCID: PMC7080638.
  44. Kammerlander H., Nielsen J., Knudsen T. et al. Anti-TNF-α use during the third trimester of pregnancy in women with moderate-severe inflammatory bowel disease and the risk of preterm birth and low birth weight. Inflamm Bowel Dis. 2017; 23(11): 1916–23. https://doi.org/10.1097/MIB.0000000000001234. PMID: 28858070.
  45. Mahadevan U., Vermeire S., Lasch K. et al. Vedolizumab exposure in pregnancy: Outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017; 45(7): 941–50. https://doi.org/10.1111/apt.13960. PMID: 28169436.
  46. Moens A., van der Woude C.J., Julsgaard M. et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: Results of the European CONCEIVE study. Aliment Pharmacol Ther. 2020; 51(1): 129–38. https://doi.org/10.1111/apt.15539. PMID: 31692017.
  47. Gotestam Skorpen C., Hoeltzenbein M., Tincani A. et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016; 75(5): 795–810. https://doi.org/10.1136/annrheumdis-2015-208840. PMID: 26888948.
  48. Venturin C., Nancey S., Danion P. et al. Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: Case-report and review of the literature. BMC Gastroenterol. 2017; 17(1): 80. https://doi.org/10.1186/s12876-017-0633-6. PMID: 28629323. PMCID: PMC5477379.
  49. Klenske E., Osaba L., Nagore D. et al. Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn’s disease. J Crohns Colitis. 2019; 13(2): 267–69. https://doi.org/10.1093/ecco-jcc/jjy153. PMID: 30388211.
  50. Mahadevan U., Dubinsky M.C., Su C. et al. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis. 2018; 24(12): 2494–500. https://doi.org/10.1093/ibd/izy160. PMID: 29982686. PMCID: PMC6262193.
  51. Mahadevan U., Robinson C., Bernasko N. et al. Inflammatory bowel disease in pregnancy clinical care pathway: A report from the American Gastroenterological Association IBD parenthood project working group. Gastroenterology. 2019; 25(4): 627–41. https://doi.org/1010.1053/j.gastro.2018.12.022. PMID: 30821832.
  52. Nielsen O.H., Maxwell C., Hendel J. IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol. 2014; 11(2): 116–27. https://doi.org/1010.1038/nrgastro.2013.135. PMID: 23897285.
  53. Plauborg A.V., Hansen A.V., Garne E. Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease. Birth Defects Res A Clin Mol Teratol. 2016; 106(6): 494–99. https://doi.org/1010.1002/bdra.23509. PMID: 27301563.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies